Giving thanks for the brave volunteers who participate in HD clinical trials

When a building catches fire, most of us instinctively move back. We watch from the sidewalk, hoping the flames die down, grateful for any distance between us and the danger.

Firefighters are different. They hear the alarm, size up the risk, and move toward the heat, knowing there are no guarantees, only training, courage, and the hope that their actions will protect others.

That image has been on my mind as I think about Sarepta Therapeutics’ latest news about SRP‑1005, its investigational treatment for Huntington’s disease (HD). In a previous column, I wrote about the moment the company submitted a clinical trial application — the sound of the first alarm bell.

Now Medsafe, the medical regulatory body run by New Zealand’s Ministry of Health, has approved that application, clearing the way for INSIGHTT, the first‑in‑human trial of SRP-1005, to begin later this year. Somewhere out there are about two dozen people with HD who will soon be asked if they are willing to walk into the building instead of staying on the sidewalk.

Recommended Reading

January 27, 2021 Columns by B.J. Viau

Got Questions About Joining a Huntington’s Clinical Trial?

Fighting the flames

SRP‑1005 is a small interfering RNA therapy designed to “knock down” the harmful huntingtin protein in key brain regions affected by HD. In this Phase 1, multicenter trial, participants will receive the drug via injections under the skin while researchers focus on safety and tolerability, making sure the “hose” doesn’t spray where it shouldn’t and that the pressure is just right. It is the scientific version of a firefighter checking their gear before stepping through the door.

When I picture those trial volunteers, I don’t see statistics or enrollment targets. I see people getting early morning blood draws, rearranging work schedules, and explaining to worried spouses why they are choosing to take on extra risk in a life already full of it. I imagine them signing consent forms with the same quiet resolve a firefighter might feel when pulling on their gear, not because they are fearless, but because they believe someone has to go first to fight the flames.

As a husband and father in an HD‑affected family, my instinct is to keep my wife, Jill, and our daughter, Alexus, far from any additional danger. Yet I know that every future treatment we dream of will exist because other families allowed their loved ones to step closer to the fire. Their willingness to face uncertainty today is what makes tomorrow’s “all clear” even possible.

So, as SRP‑1005 moves into the INSIGHTT study, that is the theme I keep returning to: the quiet bravery of people who see the same burning building the rest of us see and choose to step toward it. They are not running in alone; everyone who helps bring a medication from idea to reality is right there with them. But the volunteers are the ones who step through the door first and feel the heat most directly.

One day, I hope we will talk about HD treatments the way we talk about smoke alarms and sprinkler systems — as standard safety features, not miracles. When that day comes, I hope the story includes a chapter about the early volunteers in trials like this one, the HD “firefighters” who helped discover what worked, what didn’t, and what needed to be rebuilt from the ground up.

Until then, from my spot on the figurative sidewalk, I am cheering for them with all the gratitude a hope-filled, pun‑loving husband can muster. If courage had a uniform in the HD world, it might look less like a helmet and more like a hospital bracelet, but the heart underneath is exactly the same.

Note: Huntington’s Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Huntington’s Disease News or its parent company, Bionews, and are intended to spark discussion about issues pertaining to Huntington’s disease.